295 related articles for article (PubMed ID: 29494728)
1. Treatment of Advanced Non-Small Cell Lung Cancer in 2018.
Doroshow DB; Herbst RS
JAMA Oncol; 2018 Apr; 4(4):569-570. PubMed ID: 29494728
[No Abstract] [Full Text] [Related]
2. Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets.
Smit EF; Baas P
Nat Rev Clin Oncol; 2016 Feb; 13(2):75-6. PubMed ID: 26718109
[No Abstract] [Full Text] [Related]
3. A banner year for immunotherapy and targeted therapy.
Carlisle JW; Ramalingam SS
Nat Rev Clin Oncol; 2019 Feb; 16(2):79-80. PubMed ID: 30538305
[No Abstract] [Full Text] [Related]
4. [The revolution of immuno-oncology therapy: review of immune checkpoint inhibitors efficacy].
Dubois M; Ardin C; André F; Scherpereel A; Mortier L
Med Sci (Paris); 2019 Dec; 35(12):937-945. PubMed ID: 31903897
[TBL] [Abstract][Full Text] [Related]
5. Recent clinical trials of immunotherapy in non-small-cell lung cancer.
Gkolfinopoulos S; Mountzios G
Immunotherapy; 2019 Apr; 11(6):461-466. PubMed ID: 30860438
[No Abstract] [Full Text] [Related]
6. An early look at selective RET inhibitor resistance: new challenges and opportunities.
Lin JJ; Gainor JF
Br J Cancer; 2021 May; 124(11):1757-1758. PubMed ID: 33758332
[TBL] [Abstract][Full Text] [Related]
7. ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy.
Rosell R; Karachaliou N; Wolf J; Ou SH
Lancet Respir Med; 2014 Dec; 2(12):966-8. PubMed ID: 25466349
[No Abstract] [Full Text] [Related]
8. The changing landscape of thoracic malignancies.
Melosky B; Hirsh V
Curr Oncol; 2018 Jun; 25(Suppl 1):S5-S6. PubMed ID: 29910641
[No Abstract] [Full Text] [Related]
9. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
10. [Not Available].
Fabre E; Pécuchet N; Cadranel J
Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
[TBL] [Abstract][Full Text] [Related]
11. Evolving Treatment Options for Lung Cancer.
Morgensztern D; Herbst RS
Hematol Oncol Clin North Am; 2017 Feb; 31(1):xiii-xiv. PubMed ID: 27912837
[No Abstract] [Full Text] [Related]
12. [Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].
Greillier L; Barlesi F
Rev Mal Respir; 2012 Jan; 29(1):4-6. PubMed ID: 22240212
[No Abstract] [Full Text] [Related]
13. Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Sandler AB
Oncology (Williston Park); 2006 May; 20(6):626-8. PubMed ID: 16773846
[No Abstract] [Full Text] [Related]
14. [Immunotherapy in lung cancer: New concepts].
Goubet AG; Livartowski A; Romano E
Rev Mal Respir; 2018 Jun; 35(6):642-651. PubMed ID: 29941206
[TBL] [Abstract][Full Text] [Related]
15. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
Ettinger DS; Aisner DL; Wood DE; Akerley W; Bauman J; Chang JY; Chirieac LR; D'Amico TA; Dilling TJ; Dobelbower M; Govindan R; Gubens MA; Hennon M; Horn L; Lackner RP; Lanuti M; Leal TA; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel SP; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Stevenson J; Swanson SJ; Tauer K; Yang SC; Gregory K; Hughes M
J Natl Compr Canc Netw; 2018 Jul; 16(7):807-821. PubMed ID: 30006423
[TBL] [Abstract][Full Text] [Related]
16. 16th World Conference on Lung Cancer.
Landman A
Lancet Oncol; 2015 Oct; 16(13):1290. PubMed ID: 26387750
[No Abstract] [Full Text] [Related]
17. In search of the philosopher’s stone: The ALCHEMIST study for lung cancer.
Veeramachaneni N; Wigle D; Boughey JC
Bull Am Coll Surg; 2017 Mar; 102(3):37-8. PubMed ID: 28920661
[No Abstract] [Full Text] [Related]
18. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
[TBL] [Abstract][Full Text] [Related]
19. Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?
Remon J; Hendriks L; Aspeslagh S; Besse B
J Thorac Oncol; 2019 Oct; 14(10):1701-1703. PubMed ID: 31420287
[No Abstract] [Full Text] [Related]
20. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
